A healthtech data room should show what the clinical AI product is intended to do, what has actually been demonstrated and what work remains before the next commercial milestone. Safety evidence belongs beside the product and financial story, not in a separate folder whose assumptions contradict the pitch deck.
The index below is an editorial recommendation, not a claim that every investor requires the same documents. It draws on regulatory and lifecycle-development sources checked on 13 October 2026, including the good machine learning practice principles.
Make the product story consistent before making it persuasive
Imagine a fictional founder describing an AI assistant as ready to automate follow-up decisions. The demonstration requires clinician approval, the study evaluated only draft summaries and the intended-purpose statement excludes autonomous actions. Each document may be understandable on its own, but together they present incompatible claims.
A useful diligence exercise starts by comparing the pitch, website, product specification, evaluation protocol and planned release. The MHRA's intended-purpose guidance supports specifying the actual function, users, population and environment. The commercial narrative should not silently extend beyond those boundaries.
This does not require removing ambition from the pitch. It requires distinguishing the current product, the next proposed milestone and the broader roadmap. An investor can then understand which capabilities exist and which depend on further evidence, engineering or assessment.
A proposed safety-and-regulatory diligence index
The following contents page is intended to help a reviewer navigate the decision. It is not a regulatory submission template or evidence that the fictional company has completed any of the work.
| Data-room section | Core content | Question it should answer |
|---|---|---|
| Product and scope | Intended purpose, current functions and exclusions | What is actually being built and sold? |
| Evidence register | Completed studies, test reports and configuration links | Which claims are demonstrated? |
| Risk and controls | Hazard analysis, control status and unresolved issues | What could go wrong, and what addresses it? |
| Regulatory pathway | Jurisdiction-specific assessment rationale and milestones | What decisions are needed before the proposed market step? |
| Dependencies | Model suppliers, data sources, integrations and change exposure | Which assumptions depend on another organisation? |
| Deployment readiness | Required users, training, local controls and fallback | What must a customer provide for the workflow to operate? |
| Lifecycle ownership | Monitoring, incident response, updates and withdrawal | Who remains responsible after launch? |
| Resource plan | Remaining work, named owners and dependencies | What must the next funding actually enable? |
A concise summary should link to the underlying evidence rather than replace it. An investor should be able to move from a claim in the deck to the relevant evaluation and understand its limitations.
Separate demonstrated performance from planned work
An evidence register can use plain-language states: completed and reviewed, completed with unresolved questions, in progress, planned or not yet specified. The states should describe reality rather than create a reassuring impression of progress.
For the fictional follow-up product, a simulated study may establish that the prototype generates relevant drafts under particular conditions. It would not establish reduced NHS workload, safe autonomous execution or improved patient outcomes. Those claims require different evidence.
The good machine learning practice principles emphasise representative evidence, relevant testing and the human-AI team. A founder should therefore identify the evaluated users and workflow, not only the underlying model's performance. Planned live evaluation should remain labelled as planned until it has actually occurred.
Link every result to the version that produced it
A paper or internal report can become misleading when attached to a materially different product. The data room should identify the model, retrieval sources, prompts, interface and permissions relevant to each evaluation.
The record does not need to reproduce every technical detail in the investor summary. It does need a reliable link to the configuration and an explanation of meaningful changes. A claim about a draft-only prototype should not be carried over to an action-taking release without assessment.
The joint predetermined change-control principles support bounded changes and lifecycle evidence. They do not imply that a manufacturer can describe all future releases as covered by one initial evaluation or one prospective plan.
Show unresolved risk without turning the register into theatre
A useful risk entry identifies the issue, potential consequence, proposed control, evidence status and owner. It also explains which decision depends on resolution. A long list of generic risks without release implications is less informative than a shorter register tied to the product.
For example, the fictional company may not yet have demonstrated safe handling of an interrupted external action. That should be linked to the restriction preventing autonomous execution until the necessary evidence exists. It should not be hidden behind a statement that users can always contact support.
Not every gap has the same significance. Some may limit the initial market, others may delay a feature, and some may require a different architecture. The resource plan should make those consequences visible instead of treating all outstanding work as routine documentation.
External dependencies belong in the investment story
A third-party model, licensed source or clinical-system integration can be a sensible design choice. The relevant diligence question is what happens if that dependency changes, becomes unavailable or no longer supports the proposed use.
A proposed register should distinguish contractual commitments from assumptions. It should explain notification arrangements, available alternatives and what the product will stop doing if an essential dependency fails. Claims about privacy, data access or model stability should be supported by the actual relevant arrangements rather than the supplier's general reputation.
Scarlet's published discussion of third-party LLM devices identifies such dependencies as questions for the manufacturer. The existence of an external component does not automatically invalidate the business, but concealing its importance makes the safety and commercial story less credible.
Explain the work after market entry
A founder should not imply that completing an assessment ends safety expenditure. Monitoring, changes, incident investigation, support and deployment communication need continuing ownership and resources.
For applicable English NHS customers, DCB0129 and DCB0160 also distinguish the manufacturer's and adopter's responsibilities. A supplier cannot assume that a customer will invent missing controls, while a customer cannot assume that all local risks were settled by the manufacturer's assessment.
The data room should explain the proposed handover and operating relationship. This is especially important when a revenue forecast depends on deploying the same product across settings with different staffing, records and clinical pathways.
Make the funding milestone evidence-based
A useful milestone might be completion of a defined evaluation, resolution of specified release risks or submission under an established assessment route. "Become clinically validated" is too vague unless the product claim and required evidence are explicit.
Our recommendation is to connect each milestone to the work, owner, dependencies and decision it enables. Budget figures should come from the company's actual plan and quotations, not generic estimates inserted to make the file look complete.
As described on 13 October 2026, Insights by iatroX offers clinical safety, validation and regulatory-readiness support. That advice can help founders expose inconsistencies and organise the evidence, but it does not guarantee funding, certification or clinical success. A credible data room demonstrates that the team understands what it has earned the right to claim, and what remains to be proved.
Frequently asked questions
Does every investor require this exact safety data room?
No. This is a recommended organising framework, and diligence expectations vary with the investor, company stage, product and market.
Should founders disclose studies that are still planned?
Yes, but clearly distinguish them from completed evidence. Explain which product or commercial decisions remain dependent on their results.
Is a certification milestone enough to describe post-launch readiness?
No. The operating plan should also address deployment, changes, monitoring, incident response and the resources needed to maintain those responsibilities.